Kadmon

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

You can watch Kadmon and buy or sell other stocks, options, and ETFs commission-free!

About KDMN

Kadmon Corporation, a biopharmaceutical company, offers products and services for the treatment and management of hepatitis C. Its products include Ribasphere RibaPak (ribavirin, USP) tablets, which help to reduce pill burden while providing patients with treatment that is biologically equivalent to other ribavirin medications; INFERGEN (interferon alfacon-1) to treat chronic hepatitis C in patients 18 years of age or older with compensated liver disease; Ribasphere (ribavirin, USP) tablets and capsules, which are antiviral medications for use in combination with other drugs for the treatment of chronic hepatitis C; and KD020, a reversible tyrosine kinase inhibitor that targets EGFR, HER2, VEGFR 2/3, and Src in autosomal dominant polycystic kidney disease (PKD). 

CEO
Gustavo J. Pesquin, MBA; Harlan W. Waksal, MD
CEOGustavo J. Pesquin, MBA; Harlan W. Waksal, MD
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2010
Founded2010
Employees
Employees

KDMN Key Statistics

Market cap
1.68B
Market cap1.68B
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
4.56M
Average volume4.56M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$9.50
52 Week high$9.50
52 Week low
$3.36
52 Week low$3.36

KDMN Earnings

-$0.20
-$0.13
-$0.07
$0.00
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Expected Nov 3, Pre-Market
ActualExpected Nov 3, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.